Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Enzymatics Enriches NGS with AMP
Targeted Sequencing Technology Enhances Gene Mutation Identification and Discovery
- In transforming itself from a reagents supplier to a next-generation sequencing (NGS) applications company, Enzymatics is advancing the genomics industry. While Enzymatics continues to support and expand its fast-growing core business—reagents and kits for original equipment manufacturers—it is also taking advantage of a new technology—Anchored Multiplex PCR (AMP™) chemistry. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.